$ABBV AbbVie forms a breakout set up pattern.

2017년 11월 15일

AbbVie, although overvalued, and with little revenue diversification still has the most profitable drug on the US pharmaceutical market, Humira, with a longstanding patent. ABBV still have plenty of momentum to beat it's median price target of $95.